Professor, Medicine, Case Western Reserve Univ Sch of Med
Oncology
Dr. Lyndsay N. Harris, MD
|
|
Give Review
Lyndsay Harris works in the field of Oncology. She received awards:"America's Top Doctors". Lyndsay Harris has written publications. She has 52 publications published with PubMed. The lastest paper is: 'Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Pra...' Dr. Lyndsay N. Harris accepts Medicare payments and is listed with Medicare.gov.
Publications
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Pra...
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus ...
- Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast Cancer.
- Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
- Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast Cancer after progression on prior trastuzumab therapy.
- Tumor Markers in Older Patients With Early Breast Cancer: Why Are We Still Doing Useless Tests?
- The renaissance of endocrine therapy in breast Cancer.
- Triple-negative breast Cancer in the post-genomic era.
- Translating next generation sequencing to practice: Opportunities and necessary steps.
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast Cancer in the North Cent...
- HDAC inhibitors induce transcriptional repression of high copy number genes in breast Cancer through elongation blockade.
- PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast Cancer.
- Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria.
- Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
- Optimal Tumor Sampling for Immunostaining of Biomarkers in Breast Carcinoma.
- Molecular predictors of response to therapy for breast Cancer.
- C-MYC alterations and association with patient outcome in early-stage HER2-positive breast Cancer from the north central Cancer treatment group N9831 adjuvant trastuzu...
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
- Global variation in CYP2C8-CYP2C9 functional haplotypes.
- Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early Breast...
- Trastuzumab-induced HER reprogramming in "resistant" Breast carcinoma cells.
- VEGF as a marker for outcome among advanced breast Cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
- Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast Cancer.
- Systemic endocrine instigation of indolent tumor growth requires osteopontin.
- Molecular definition of Breast tumor heterogeneity.
- Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast Cancer.
- Declining plasma fibrinogen alpha fragment identifies HER2-positive breast Cancer patients and reverts to normal levels after surgery.
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human Cancers.
- A role for the scaffolding adapter GAB2 in breast Cancer.
- Requirement for CDK4 kinase function in breast Cancer.
- Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast Cancer chemotherapy.
- HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary Breast tumors.
- Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast Cancer: Cancer and leukemia group B trial 9342.
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast Cancer: multicenter phase II trial with clinical outcomes, analysis of seru...
- Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast Cancer...
- The HER2 extracellular domain as a prognostic and predictive factor in breast Cancer.
- Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast Cancer.
- A Radio-genomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores.
- Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
- A germline mutation in the BRCA1 3'UTR predicts Stage IV breast Cancer.
- Molecular phenotypes in triple negative breast Cancer from african american patients suggest targets for therapy.
- Circulating tumor cells as predictors of response and failure in breast Cancer patients treated with preoperative chemotherapy.
- Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data.
- Molecular subtypes of breast Cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
- Triple negative breast Cancer: current understanding of biology and treatment options.
- Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear Cells: relevance for detection of circulating tumor Cells.
- Genomic analysis from tissue core biopsies: standard of care for the future?
- Circulating tumor cells in HER-2 positive metastatic breast Cancer patients treated with trastuzumab and chemotherapy.
- Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast Cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
- Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade Astrocytoma.
Schools
University of Alberta Faculty of Medicine And Dentistry
Conditions Treated
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
Education
-
Georgetown University Hospital -
University of Alberta Faculty of Medicine
Hospital
-
University Hospitals Case Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Francine M. Foss, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tara B. Sanft, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin W. Hofstatter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan A. Baumgart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy S. Herbst, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mario Sznol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah B. Goldberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Warren D. Shlomchik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven D. Gore, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|